Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations.
Allan H YoungMohamed AbdelghaniMario F JuruenaViktoriya L NikolovaRamin NilforooshanPublished in: Neuropsychiatric disease and treatment (2023)
Providing additional treatment options for the management of TRD, such as esketamine nasal spray, is likely to be key to improving the long-term outcomes of this underserved patient population.